CALA Calithera Biosciences Inc.

-0.05  -1%
Previous Close 6.41
Open 6.41
Price To Book 1.95
Market Cap 247007759
Shares 38,837,698
Volume 87,859
Short Ratio
Av. Daily Volume 173,023

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial ongoing but will not pursue development.
CB-839 with paclitaxel
Triple negative breast cancer
Phase 2 top-line data due 2H 2019.
CB-839 + AFINITOR (everolimus)‎ - ENTRATA
Clear cell renal cell carcinoma
Phase 1 oral presentation at ASCO, June 5, 2017.
Solid tumors - cancer
Phase 1/2 enrollment commenced August 2016. Oral presentation November 11, 2017 at 32nd Annual Meeting of the Society for Immunotherapy of Cancer (SITC).
CB-839 + nivolumab
Renal cell carcinoma, malignant melanoma and non-small cell lung cancer
Phase 2 poster at ASCO GU February 16, 2019 noted 5/13 ORR.
CB-839 + Cabozantinib (CANTATA)
Renal cell carcinoma
Phase 2 portion of trial is ongoing.
CB-839 + Panitumumab
Colorectal cancer
Phase 1 poster at ASCO June 4, 2018 8am.
CB-839 + Capecitabine
Solid tumors
Phase 1 presentation at ASCO June 2018. PFS 26 weeks.
CB-839 plus capecitabine
Solid tumors
Phase 1/2 trial to be initiated 1Q 2019.
CB-839 plus talazoparib
Triple negative breast cancer
Phase 1/2 data due 2H 2019.
Solid tumors
Phase 1/2 trial to be initiated 1Q 2019.
Ibrance and talazoparib + CB-839
KRAS mutated NSCLC
Phase 1 trial initiation announced February 21, 2019 with trial completion 2019.
Cystic fibrosis

Latest News

  1. Edited Transcript of CALA earnings conference call or presentation 7-Mar-19 9:30pm GMT
  2. Calithera Biosciences Reports Fourth Quarter 2018 Financial Results and Recent Highlights
  3. Calithera to Present at Cowen & Company 39th Annual Healthcare Conference
  4. Calithera Biosciences to Report Fourth Quarter 2018 Financial Results on Thursday, March 7, 2019
  5. Calithera Biosciences Announces CB-708 Preclinical Data Presentation at the AACR Annual Meeting 2019
  6. Calithera to Participate in the 8th Annual SVB Leerink Global Healthcare Conference
  7. Calithera Biosciences Initiates Phase 1 Trial of Arginase Inhibitor CB-280 for the Treatment of Cystic Fibrosis
  8. Updated Results from Phase 1 Study of Telaglenastat (CB-839) to be Presented at 2019 ASCO Genitourinary Cancer Symposium
  9. Calithera Biosciences Completes Patient Enrollment in Randomized Phase 2 ENTRATA Trial of Telaglenastat (CB-839) and Everolimus in Renal Cell Carcinoma
  10. Analysis: Positioning to Benefit within Rollins, Hospitality Properties Trust, Exact Sciences, Tenet Healthcare, Entergy, and Calithera Biosciences — Research Highlights Growth, Revenue, and Consolidated Results
  11. What Did Calithera Biosciences, Inc.’s (NASDAQ:CALA) CEO Take Home Last Year?
  12. Calithera Biosciences Provides Corporate Updates and Announces Key Executive Promotions to Drive Continued Growth of the Company’s Pipeline
  13. Calithera Biosciences to Participate in the 2018 Citi Global Healthcare Conference
  14. Intrinsic Calculation For Calithera Biosciences Inc (NASDAQ:CALA) Shows Investors Are Overpaying
  15. Edited Transcript of CALA earnings conference call or presentation 7-Nov-18 10:00pm GMT
  16. New Research: Key Drivers of Growth for AxoGen, Spirit Realty Capital, e.l.f. Beauty, Minerva Neurosciences, Par Pacific, and Calithera Biosciences — Factors of Influence, Major Initiatives and Sustained Production
  17. Calithera (CALA) Reports Q3 Loss, Lags Revenue Estimates
  18. Calithera: 3Q Earnings Snapshot
  19. Calithera Biosciences Reports Third Quarter 2018 Financial Results and Recent Highlights
  20. Calithera Biosciences to Report Third Quarter 2018 Financial Results on Wednesday, November 7, 2018